肝细胞癌超声诊疗基础研究进展：从诊断、治疗到诊疗一体化

汪思睿; 顾卫琪; 沈玉婷; 尹豪豪; 徐辉雄

doi:10.12449/JCH260702

肝细胞癌超声诊疗基础研究进展：从诊断、治疗到诊疗一体化

DOI: 10.12449/JCH260702

汪思睿¹,
顾卫琪¹,
沈玉婷^{1, 2, 3},
尹豪豪^{1, 2, 3},
徐辉雄^{1, 2, 3, , ,}

1.
复旦大学附属中山医院超声科，上海 200032
2.
复旦大学超声医学与工程研究所，上海 200032
3.
上海市影像医学研究所，上海 200032

基金项目:

国家自然科学基金 (82302206);

国家自然科学基金 (82430064);

国家重点研发计划 (2023YFC2414204);

国家重点研发计划 (2023YFC2414203);

国家重点研发计划 (2023YFC2414202);

复旦大学附属中山医院科研发展基金 (2022ZSQD07);

上海市扬帆计划 (23YF1441600);

中国博士后科学基金 (2023TQ0073)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：汪思睿、顾卫琪负责撰写论文初稿；沈玉婷、尹豪豪负责论文的修改完善；徐辉雄负责指导文章思路并审阅定稿。

详细信息

通信作者:
徐辉雄， xuhuixiong@126.com （ORCID： 0000-0002-9878-8590）

计量
- 文章访问数: 5
- HTML全文浏览量: 0
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2026-05-26
- 录用日期: 2026-07-17
- 出版日期: 2026-07-25

Advances in basic research on ultrasound diagnosis and treatment of hepatocellular carcinoma: From diagnosis and treatment to integrated management

Sirui Wang¹,
Weiqi Gu¹,
Yuting Shen^{1, 2, 3},
Haohao Yin^{1, 2, 3},
Huixiong Xu^{1, 2, 3
, ,
,}

1.
Department of Ultrasound，Zhongshan Hospital，Fudan University，Shanghai 200032，China
2.
Institute of Ultrasound in Medicine and Engineering，Fudan University，Shanghai 200032，China
3.
Shanghai Institute of Medical Imaging，Shanghai 200032，China

Research funding:

National Natural Science Foundation of China (82302206);

National Natural Science Foundation of China (82430064);

National Key R&D Program of China (2023YFC2414204);

National Key R&D Program of China (2023YFC2414203);

National Key R&D Program of China (2023YFC2414202);

Scientific Development Fund of Zhongshan Hospital, Fudan University (2022ZSQD07);

Shanghai Sailing Program (23YF1441600);

China Postdoctoral Science Foundation (2023TQ0073)

More Information

Corresponding author: Xu Huixiong， xuhuixiong@126.com （ORCID： 0000-0002-9878-8590）

摘要

摘要: 肝细胞癌（HCC）的精准诊疗面临肿瘤微环境复杂、治疗抵抗及易复发转移等重大挑战。近年来，超声技术已突破传统筛查定位功能，逐渐发展为兼具能量激活、靶向递送、局部消融、免疫调控和疗效反馈能力的多维治疗平台。本文系统综述了超声技术在HCC治疗及诊疗一体化基础研究中的最新进展。在治疗方面，以微泡/纳泡递送、声动力疗法、高强度聚焦超声及组织碎化术为代表的干预策略，不仅实现了病灶的原位物理毁损，更通过与声遗传学、代谢重编程及免疫化疗的深度协同，有效逆转了肿瘤的免疫耐受网络。在诊疗一体化方面，新型声敏纳米递送系统构筑了能量激活与靶向控释的平台。针对该领域面临的转化瓶颈，建议未来建立标准化的临床前治疗声学参数共识，以期为HCC的个体化精准诊疗确立新的转化范式。
- 癌，肝细胞 /
- 超声检查 /
- 分子成像 /
- 声动力疗法 /
- 体外冲击波疗法 /
- 诊断 /
- 治疗学
Abstract: The precise diagnosis and treatment of hepatocellular carcinoma （HCC） face major challenges such as the complexity of tumor microenvironment， treatment resistance， and a high risk of recurrence and metastasis. In recent years， ultrasound technology has moved beyond its traditional role in screening and localization， gradually evolving into a multidimensional therapeutic platform capable of energy activation， targeted delivery， local ablation， immune modulation， and therapeutic feedback. This article systematically reviews the latest advances in the basic research on ultrasound techniques in HCC treatment and integrated management. In terms of treatment， intervention strategies represented by microbubble/nanobubble-mediated delivery， sonodynamic therapy， high-intensity focused ultrasound， and histotripsy not only enable in situ physical destruction of lesions， but also effectively reverse tumor immune tolerance networks through deep synergy with sonogenetics， metabolic reprogramming， and immunochemotherapy. In terms of integrated management， novel sonosensitive nanodelivery systems provide a platform for energy activation and targeted controlled release. To address the translational bottlenecks in this field， it is recommended to develop standardized consensus on preclinical therapeutic ultrasound parameters， in order to establish a new translational paradigm for individualized precise diagnosis and treatment of HCC.
- Carcinoma， Hepatocellular /
- Ultrasonography /
- Molecular Imaging /
- Sonodynamic Therapy /
- Extracorporeal Shockwave Therapy /
- Diagnosis /
- Therapeutics

HTML全文

图 1 肝细胞癌超声治疗与诊疗一体化的主要研究策略

Figure 1. Major research strategies for ultrasound therapy and theranostics in hepatocellular carcinoma

下载: 全尺寸图片幻灯片

图附录A～E见二维码

下载: 全尺寸图片幻灯片

参考文献(82)

[1]	Siegel R L, Kratzer T B, Wagle N S, et al. Cancer statistics, 2026[J]. CA Cancer J Clin, 2026, 76: e70043. DOI: 10.3322/caac.70043.
[2]	Mauro E, de Castro T, Zeitlhoefler M, et al. Hepatocellular carcinoma: Epidemiology, diagnosis and treatment[J]. JHEP Rep, 2025, 7( 12): 101571. DOI: 10.1016/j.jhepr.2025.101571.
[3]	Chan S L, Sun H C, Xu Y, et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: Comprehensive strategies from prevention to treatment[J]. Lancet, 2025, 406( 10504): 731- 778. DOI: 10.1016/S0140-6736(25)01042-6.
[4]	European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma[J]. J Hepatol, 2025, 82( 2): 315- 374. DOI: 10.1016/j.jhep.2024.08.028.
[5]	Vogel A, Chan S L, Dawson L A, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2025, 36( 5): 491- 506. DOI: 10.1016/j.annonc.2025.02.006.
[6]	Singal A G, Llovet J M, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78( 6): 1922- 1965. DOI: 10.1097/HEP.0000000000000466.
[7]	Sang W, Fan H L, Huang Y J, et al. New strategies for tumor diagnosis and therapy with ultrasound assisted by nanomaterials[J]. Ultrason Sonochem, 2025, 121: 107542. DOI: 10.1016/j.ultsonch.2025.107542.
[8]	Moradi Kashkooli F, Hornsby T K, Kolios M C, et al. Ultrasound-mediated nano-sized drug delivery systems for cancer treatment: Multi-scale and multi-physics computational modeling[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2024, 16( 1): e1913. DOI: 10.1002/wnan.1913.
[9]	Song X R, Zhang Q, Chang M Q, et al. Nanomedicine-enabled sonomechanical, sonopiezoelectric, sonodynamic, and sonothermal therapy[J]. Adv Mater, 2023, 35( 31): e2212259. DOI: 10.1002/adma.202212259.
[10]	Padilla F, Brenner J, Prada F, et al. Theranostics in the vasculature: Bioeffects of ultrasound and microbubbles to induce vascular shutdown[J]. Theranostics, 2023, 13( 12): 4079- 4101. DOI: 10.7150/thno.70372.
[11]	Tu J, Yu A C H. Ultrasound-mediated drug delivery: Sonoporation mechanisms, biophysics, and critical factors[J]. BME Front, 2022, 2022: 9807347. DOI: 10.34133/2022/9807347.
[12]	Zhang C J, Zhang Q Y, Xu Q, et al. Ultrasound targeted microbubbles for theranostic applications in liver diseases: From molecular imaging to targeted therapy[J]. Drug Deliv, 2025, 32( 1): 2541656. DOI: 10.1080/10717544.2025.2541656.
[13]	Krolak C, de Koninck L, Gu S, et al. Ultrasound cavitation therapy: Inducing tumor drug delivery and blood flow changes with clinical ultrasound tools[J]. J Control Release, 2026, 393: 114748. DOI: 10.1016/j.jconrel.2026.114748.
[14]	Zhang C J, Chen Y Z, Han J X, et al. Ultrasound nanobubble-based combinational strategies of loaded miR-107-3p and CD133 Ab for anti-PD-L1 and anti-hepatocellular cancer stem cells[J]. Int J Pharm, 2025, 670: 125140. DOI: 10.1016/j.ijpharm.2024.125140.
[15]	Liu Y, Xie Q, Ma Y, et al. Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice[J]. Int J Pharm, 2022, 629: 122352. DOI: 10.1016/j.ijpharm.2022.122352.
[16]	Liu Y, Han J X, Liu C Q, et al. Enhancing the tumoricidal efficacy of the nanobubbles-mediated PD-L1 inhibition and immunogenic cell death in mice[J]. Front Immunol, 2025, 16: 1672324. DOI: 10.3389/fimmu.2025.1672324.
[17]	Kim D, Lee J H, Moon H, et al. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization(TACE) formulation on rabbit VX2 liver cancer model[J]. Theranostics, 2021, 11( 1): 79- 92. DOI: 10.7150/thno.45348.
[18]	Tran N A, Ta H T. 2D materials in ultrasound-driven cancer therapies: Correlating material characteristics with therapeutic performance[J]. Coord Chem Rev, 2026, 549: 217366. DOI: 10.1016/j.ccr.2025.217366.
[19]	Son S, Kim J H, Wang X W, et al. Multifunctional sonosensitizers in sonodynamic cancer therapy[J]. Chem Soc Rev, 2020, 49( 11): 3244- 3261. DOI: 10.1039/c9cs00648f.
[20]	Peng Y, Li Z, Zhou L, et al. Drug repurposing: Isosorbide mononitrate enhances tumor accumulation to augment sonodynamic therapy for hepatocellular carcinoma[J]. J Nanobiotechnol, 2025, 23( 1): 587. DOI: 10.1186/s12951-025-03674-7.
[21]	Lyu Y H, Li Q, Xie S N, et al. Synergistic ultrasound-activable artificial enzyme and precision gene therapy to suppress redox homeostasis and malignant phenotypes for controllably combating hepatocellular carcinoma[J]. J Am Chem Soc, 2025, 147( 3): 2350- 2368. DOI: 10.1021/jacs.4c10997.
[22]	Liu S X, Ma J J, Xue E Y, et al. Polymeric phthalocyanine-based nanosensitizers for enhanced photodynamic and sonodynamic therapies[J]. Adv Healthc Mater, 2023, 12( 23): e2300481. DOI: 10.1002/adhm.202300481.
[23]	Liang J, Ding H. Activatable sulfur dioxide nanosonosensitizer enables precisely controllable sono-gaseous checkpoint trimodal therapy for orthotopic hepatocellular carcinoma[J]. Ultrasound Med Biol, 2025, 51: S280. DOI: 10.1016/j.ultrasmedbio.2025.11.608.
[24]	Wei W Y, Wang H, Ren C R, et al. Ultrasmall enzyodynamic PANoptosis nano-inducers for ultrasound-amplified hepatocellular carcinoma therapy and lung metastasis inhibition[J]. Adv Mater, 2024, 36( 45): 2409618. DOI: 10.1002/adma.202409618.
[25]	Yu H L, Huang Y Q, Nong Z S, et al. In-situ grown nanocrystal TiO₂ on 2D Ti₃C₂ nanosheets with anti-tumor activity from photo-sonodynamic treatment and immunology[J]. Int J Nanomedicine, 2024, 19: 7963- 7981. DOI: 10.2147/IJN.S457112.
[26]	Lu Y J, Lu J, Hua M Y, et al. Sono-flexocatalytic tumor suppression enabled by SrTiO₃ nanoflexocatalysts[J]. Angew Chem Int Ed, 2026, 65( 7): e25868. DOI: 10.1002/anie.202525868.
[27]	Ali Zahid A, Chakraborty A, Luo W, et al. Engineering a sonotherapeutic RBC membrane-derived nanoparticle platform for the treatment of liver cancer[J]. Adv Funct Mater, 2026, 36( 31): e24571. DOI: 10.1002/adfm.202524571.
[28]	Zhang J Y, Luo X, Yang X, et al. Ultrasound-responsive nanodelivery system of GPC3-targeting and sonosensitizer for visualized hepatocellular carcinoma therapy[J]. Int J Nanomedicine, 2024, 19: 7015- 7031. DOI: 10.2147/IJN.S470847.
[29]	Xu Y, Cai X J, Wu J R, et al. Colonization of engineered bacteria enhanced lipid nanomedicine accumulation in tumors for sonodynamic immunotherapy[J]. Mater Today Bio, 2025, 33: 101943. DOI: 10.1016/j.mtbio.2025.101943.
[30]	Song Q F, Wang A N, Zhang Y Q, et al. A transformable and self-oxygenated smart probe for enhanced tumor sonodynamic therapy[J]. Acta Biomater, 2024, 184: 409- 418. DOI: 10.1016/j.actbio.2024.06.019.
[31]	Xie T A, Shan Y K, Topatana W, et al. Targeted intracellular copper reservoir enhances liver cancer immunotherapy[J]. Small, 2025, 21( 36): e02783. DOI: 10.1002/smll.202502783.
[32]	Sun Y C, Chen Y C, Wu B L, et al. Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: Enhanced antitumor efficacy and specific mechanisms[J]. J Nanobiotechnology, 2024, 22( 1): 762. DOI: 10.1186/s12951-024-02995-3.
[33]	Meng W, Chen T, Li X P, et al. A dual-targeting biomimetic nanoplatform integrates SDT/CDT/gas therapy to boost synergistic ferroptosis for orthotopic hepatocellular carcinoma therapy[J]. Adv Sci(Weinh), 2025, 12( 8): e2413833. DOI: 10.1002/advs.202413833.
[34]	Xu Q B, Zhan G T, Zhang Z L, et al. Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors[J]. Theranostics, 2021, 11( 4): 1937- 1952. DOI: 10.7150/thno.45511.
[35]	Ren C R, Deng R X, Ding J M, et al. Sonocatalytic eradication of hepatocellular carcinoma by tailoring structural defects of black indium oxide sonocatalysts and leveraging apoptosis/ferroptosis-hybridized pathways[J]. Small, 2026, 22( 19): e12436. DOI: 10.1002/smll.202512436.
[36]	Liu Y M, Li G Z, Wang G B, et al. Ultrasound-activatable nanovaccines amplify dual-modal ROS for cancer sono-immunotherapy[J]. J Control Release, 2025, 388: 114285. DOI: 10.1016/j.jconrel.2025.114285.
[37]	Yang M, Ren W Z, Cui H J, et al. Ginsenoside Rk1-loaded manganese-doped hollow titania for enhancing tumor sonodynamic therapy via upregulation of intracellular reactive oxygen species[J]. ACS Appl Mater Interfaces, 2023, 15( 17): 20800- 20810. DOI: 10.1021/acsami.3c03476.
[38]	Li Z L, Qiu G H, Guo W W, et al. Regulating HIF-2α stabilization with an intelligent switchable nanoplatform for tumor immunity reprogramming and enhanced therapy[J]. Biomaterials, 2026, 330: 124022. DOI: 10.1016/j.biomaterials.2026.124022.
[39]	Wu L C, Zhu Y J, Liu X T, et al. Hyaluronic acid coated GSH-responsive Mn(III)-pMOF-based nanosonosensitizers for cascade-catalytic enhancement of sonodynamic therapy against hepatocellular carcinoma[J]. Int J Biol Macromol, 2025, 318: 145269. DOI: 10.1016/j.ijbiomac.2025.145269.
[40]	Zhang M, Wang X H, Zhang C C, et al. A versatile nanoplatform for enhanced sonodynamic therapy via hypoxia alleviation, glutathione depletion, and calcium overload[J]. J Mater Chem B, 2025, 13( 31): 9559- 9575. DOI: 10.1039/d5tb00318k.
[41]	Wu B L, Yuan Y C, Liu J Y, et al. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma[J]. J Nanobiotechnology, 2021, 19( 1): 177. DOI: 10.1186/s12951-021-00923-3.
[42]	Yang H J, Jing H, Han X, et al. Synergistic anticancer strategy of sonodynamic therapy combined with PI-103 against hepatocellular carcinoma[J]. Drug Des Devel Ther, 2021, 15: 531- 542. DOI: 10.2147/DDDT.S296880.
[43]	Tan H Y, Tian H M, Chen Y C, et al. Comparative analysis of metabolome and transcriptomes to explore the inhibited influence of sonodynamic therapy combined with lonidamine on hepatocellular carcinoma[J]. Drug Deliv, 2025, 32( 1): 2593600. DOI: 10.1080/10717544.2025.2593600.
[44]	Wang X D, Wang C Y, Tian H M, et al. IR-820@NBs combined with MG-132 enhances the anti-hepatocellular carcinoma effect of sonodynamic therapy[J]. Int J Nanomedicine, 2023, 18: 6199- 6212. DOI: 10.2147/IJN.S431910.
[45]	Wang G N, Lu H T, Pan Y, et al. Ultrasound-sensitive targeted liposomes as a gene delivery system for the synergistic treatment of hepatocellular carcinoma[J]. Small, 2024, 20( 47): 2406182. DOI: 10.1002/smll.202406182.
[46]	Huang L X, Rong Y, Guo M H, et al. Engineered Akkermansia muciniphila vesicles for targeted pyroptosis and trained immunity to enhance immunotherapy in hepatocellular carcinoma[J]. Cell Rep Med, 2026, 7( 1): 102524. DOI: 10.1016/j.xcrm.2025.102524.
[47]	Yin H H, Sun L P, Pu Y Y, et al. Ultrasound-controlled CRISPR/Cas9 system augments sonodynamic therapy of hepatocellular carcinoma[J]. ACS Cent Sci, 2021, 7( 12): 2049- 2062. DOI: 10.1021/acscentsci.1c01143.
[48]	Xiong B, Yu J F, Wen C J, et al. Antisense oligonucleotide-loaded nanozyme reverses tumor immune suppression through sonogenetic metabolic therapy[J]. J Control Release, 2025, 387: 114236. DOI: 10.1016/j.jconrel.2025.114236.
[49]	Xu W T, Zheng J J, Zhang J Q, et al. Dual-mode treatment of hepatocellular carcinoma using RGD cyclopeptide-modified liposomes loaded with Ce6/DOX[J]. Int J Nanomedicine, 2025, 20: 3845- 3860. DOI: 10.2147/IJN.S509387.
[50]	Jiang Y F, Chen H J, Lin T, et al. Ultrasound-activated prodrug-loaded liposome for efficient cancer targeting therapy without chemotherapy-induced side effects[J]. J Nanobiotechnology, 2024, 22( 1): 2. DOI: 10.1186/s12951-023-02195-5.
[51]	Shi X X, Zhang Y, Tian Y, et al. Multi-responsive bottlebrush-like unimolecules self-assembled nano-riceball for synergistic sono-chemotherapy[J]. Small Methods, 2021, 5( 3): e2000416. DOI: 10.1002/smtd.202000416.
[52]	Gao X J, Bao K, Zhang Y Q, et al. The synergistic effects of multidrug-loaded nanocarriers improve tumor microenvironment responsive chemo-sonodynamic therapy of hepatocellular carcinoma[J]. Adv Funct Mater, 2023, 33( 29): 2215014. DOI: 10.1002/adfm.202215014.
[53]	Chen S J, Ma T L, Wang J H, et al. Macrophage-derived biomimetic nanoparticles enhanced SDT combined with immunotherapy inhibited tumor growth and metastasis[J]. Biomaterials, 2024, 305: 122456. DOI: 10.1016/j.biomaterials.2023.122456.
[54]	Chen Y Z, Luo X Q, Liu Y, et al. Targeted nanobubbles of PD-L1 MAb combined with doxorubicin as a synergistic tumor repressor in hepatocarcinoma[J]. Int J Nanomedicine, 2022, 17: 3989- 4008. DOI: 10.2147/IJN.S376172.
[55]	Yang H J, Li R, Jin S Y, et al. Targeted nanosensitizer-augmented sono-immunotherapy with STING agonist to remodel the immune microenvironment in hepatocellular carcinoma[J]. Acta Biomater, 2025, 199: 387- 397. DOI: 10.1016/j.actbio.2025.05.029.
[56]	Wu H, Gu L H, Xu J H, et al. Immunosuppressive microenvironment reprogramming by synergistic sonodynamic therapy of phthalocyanine-MOF hybrids for hepatocellular carcinoma[J]. Exploration(Beijing), 2026, 6( 2): 20250074. DOI: 10.1002/EXP.20250074.
[57]	Chen Y C, Shang H T, Wang C Y, et al. RNA-seq explores the mechanism of oxygen-boosted sonodynamic therapy based on all-in-one nanobubbles to enhance ferroptosis for the treatment of HCC[J]. International Journal of Nanomedicine, 2022, 17: 105- 123. DOI: 10.2147/IJN.S343361.
[58]	Tian H M, Shang H T, Chen Y C, et al. Sonosensitizer nanoplatforms augmented sonodynamic therapy-sensitizing shikonin-induced necroptosis against hepatocellular carcinoma[J]. Int J Nanomedicine, 2023, 18: 7079- 7092. DOI: 10.2147/IJN.S435104.
[59]	Xu Z, Khokhlova T D, Cho C S, et al. Histotripsy: A method for mechanical tissue ablation with ultrasound[J]. Annu Rev Biomed Eng, 2024, 26( 1): 141- 167. DOI: 10.1146/annurev-bioeng-073123-022334.
[60]	O’Reilly M A. Exploiting the mechanical effects of ultrasound for noninvasive therapy[J]. Science, 2024, 385( 6714): eadp7206. DOI: 10.1126/science.adp7206.
[61]	Bachu V S, Kedda J, Suk I, et al. High-intensity focused ultrasound: A review of mechanisms and clinical applications[J]. Ann Biomed Eng, 2021, 49( 9): 1975- 1991. DOI: 10.1007/s10439-021-02833-9.
[62]	Shen J, Hao J N, Chen Y N, et al. Neutrophil-mediated clinical nanodrug for treatment of residual tumor after focused ultrasound ablation[J]. J Nanobiotechnology, 2021, 19( 1): 345. DOI: 10.1186/s12951-021-01087-w.
[63]	Yang J, Liao M, Wu Z R, et al. Perfluorohexane nanodroplet-assisted mechanical high intensity focused ultrasound cavitation: A strategy for hepatocellular carcinoma treatment[J]. Acta Biomater, 2025, 195: 297- 308. DOI: 10.1016/j.actbio.2025.01.061.
[64]	Pepple A L, Guy J L, McGinnis R, et al. Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation[J]. Front Immunol, 2023, 14: 1012799. DOI: 10.3389/fimmu.2023.1012799.
[65]	Wang T Z, Han P S, Run Y, et al. Ultrasound-activated piezoelectric BZT Nanocubes mediate direct Piezocatalytic killing and reverse immunosuppressive tumor microenvironment for effective hepatocellular carcinoma therapy[J]. Int Immunopharmacol, 2026, 169: 116035. DOI: 10.1016/j.intimp.2025.116035.
[66]	Li X P, Zhou B, Fan M J, et al. Exploitation of the piezoelectricity-enabled sonophotocatalysis of Bi₂Te₃-Au nanosheets for efficient overall water splitting for energy and medical applications[J]. Nano Energy, 2024, 131: 110235. DOI: 10.1016/j.nanoen.2024.110235.
[67]	Wu S Z, Wang C F. Multi-focused acoustic radiation force impulse modulation of murine hepatic xenografts enhances nanoscale DOX@Lip delivery and therapeutic effect[J]. Int J Nanomedicine, 2025, 20: 7359- 7373. DOI: 10.2147/IJN.S522247.
[68]	Chen M C, Yu Y, Hu J Y, et al. Ultrasound-driven in situ self-assembly of drug hydrogel for enhanced hepatic artery infusion chemotherapy[J]. Mater Today, 2026, 92: 253- 268. DOI: 10.1016/j.mattod.2025.12.006.
[69]	Qiu Y J, Cao J Y, Liao J H, et al. CXCR4-targeted ultrasound microbubbles for imaging and enhanced chemotherapy/Immunotherapy in liver cancer[J]. Acta Biomater, 2025, 197: 416- 430. DOI: 10.1016/j.actbio.2025.03.018.
[70]	Deng H, Shang W T, Wang K, et al. Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles[J]. J Nanobiotechnology, 2022, 20( 1): 156. DOI: 10.1186/s12951-022-01378-w.
[71]	Chen Y P, University S, et al. Targeted thermosensitive ultrasound contrast agent-enabled ultrasound-guided precise radiofrequency ablation/immunotherapy synergistic treatment for hepatocellular carcinoma[J]. ACS Appl Nano Mater, 2026, 9( 11): 5117- 5131. DOI: 10.1021/acsanm.5c05849.
[72]	Guo T T, Wang Y, Chen D X, et al. Dual-drug loaded nanobubbles combined with sonodynamic and chemotherapy for hepatocellular carcinoma therapy[J]. Int J Nanomedicine, 2024, 19: 7367- 7381. DOI: 10.2147/IJN.S460329.
[73]	Chen Y C, Wu B L, Shang H T, et al. Sono-immunotherapy mediated controllable composite nano fluorescent probes reprogram the immune microenvironment of hepatocellular carcinoma[J]. Int J Nanomedicine, 2023, 18: 6059- 6073. DOI: 10.2147/IJN.S426297.
[74]	Lin X H, Chen S, Su Y N, et al. Ultrasound activated nanobowls with deep penetration for enhancing sonodynamic therapy of orthotopic liver cancer[J]. Adv Sci(Weinh), 2024, 11( 13): e2306301. DOI: 10.1002/advs.202306301.
[75]	Xing L J, Yang X T, Bai J H, et al. Use of UMFNPs/Ce6@MBs in multimodal imaging-guided sono-photodynamic combination therapy for hepatocellular carcinoma[J]. Biomater Sci, 2024, 13( 1): 179- 192. DOI: 10.1039/d4bm00613e.
[76]	Wang M X, Zhang N S, Li R, et al. Multimodal imaging-guided sonodynamic therapy for orthotopic liver cancer using a functionalized sonosensitizer[J]. Nano Today, 2025, 61: 102618. DOI: 10.1016/j.nantod.2024.102618.
[77]	Qiu Y J, Wu Z H, Chen Y L, et al. Nano ultrasound contrast agent for synergistic chemo-photothermal therapy and enhanced immunotherapy against liver cancer and metastasis[J]. Adv Sci, 2023, 10( 21): 2300878. DOI: 10.1002/advs.202300878.
[78]	Yan Q, Yang J Y, Chen Y B, et al. Ultrasound-activated macrophage-bomb for enhanced imaging and drug delivery in hepatocellular carcinoma[J]. Mater Des, 2024, 244: 113202. DOI: 10.1016/j.matdes.2024.113202.
[79]	Ayyami Y, Dastgir M, Yektamanesh M, et al. Advances in ultrasound-activated nano-sonosensitizers for cancer treatment: A systematic review and meta-analysis[J]. Ultrason Sonochem, 2026, 127: 107750. DOI: 10.1016/j.ultsonch.2026.107750.
[80]	Gray M D, Lyon P C, Mannaris C, et al. Focused ultrasound hyperthermia for targeted drug release from thermosensitive liposomes: Results from a phase I trial[J]. Radiology, 2019, 291( 1): 232- 238. DOI: 10.1148/radiol.2018181445.
[81]	Lyon P C, Gray M D, Mannaris C, et al. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours(TARDOX): A single-centre, open-label, phase 1 trial[J]. Lancet Oncol, 2018, 19( 8): 1027- 1039. DOI: 10.1016/S1470-2045(18)30332-2.
[82]	Eisenbrey J R, Forsberg F, Wessner C E, et al. US-triggered microbubble destruction for augmenting hepatocellular carcinoma response to transarterial radioembolization: A randomized pilot clinical trial[J]. Radiology, 2021, 298( 2): 450- 457. DOI: 10.1148/radiol.2020202321.